A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

Titre officiel

A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation

Sommaire:

The purpose of this study is to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab compared with durvalumab in participants with locally advanced, unresectable Stage III non-small cell lung cancer (NSCLC) who have received at least two cycles of concurrent platinum-based chemoradiotherapy (CRT) and have not had radiographic disease progression.

Description de l'essai

Primary Outcome:

  • Independent Review Facility (IRF) Assessed Progression Free Survival (PFS)
Secondary Outcome:
  • Overall Survival (OS)
  • Investigator-assessed PFS
  • Confirmed Overall Response Rate (ORR)
  • Duration of Response (DOR)
  • PFS Rates at 12 Months, 18 Months and 24 Months
  • OS Rates at 12 Months, 24 Months, 36 Months and 48 Months
  • Time to Death or Distant Metastasis (TTDM)
  • Time to Confirmed Deterioration (TTCD) Assessed Using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core (QLQ-C30) Score
  • Percentage of Participants With Adverse Events
  • Serum Concentration of Tiragolumab
  • Serum Concentration of Atezolizumab
  • Percentage of Participants With Anti-Drug Antibodies (ADAs) to Tiragolumab
  • Percentage of Participants With ADAs to Atezolizumab

Voir cet essai sur ClinicalTrials.gov

Intéressé(e) par cet essai?

Imprimez cette page et apportez-la chez votre médecin pour discuter de votre admissibilité à cet essai et des options de traitement. Seul votre médecin peut vous recommander pour un essai clinique.

Ressources

Société canadienne du cancer

Ces ressources sont fournies en partenariat avec Société canadienne du cancer